ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TRX Tissue Regenix Group Plc

30.50
-3.00 (-8.96%)
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00BNTXR104 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.00 -8.96% 30.50 30.00 31.00 33.50 30.50 33.50 134,892 14:35:45
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 29.49M -302k -0.0043 -70.93 23.64M
Tissue Regenix Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 33.50p. Over the last year, Tissue Regenix shares have traded in a share price range of 30.50p to 74.00p.

Tissue Regenix currently has 70,574,468 shares in issue. The market capitalisation of Tissue Regenix is £23.64 million. Tissue Regenix has a price to earnings ratio (PE ratio) of -70.93.

Tissue Regenix Share Discussion Threads

Showing 14901 to 14922 of 14925 messages
Chat Pages: 597  596  595  594  593  592  591  590  589  588  587  586  Older
DateSubjectAuthorDiscuss
20/6/2025
17:46:36
Seems to have been an active trading day by TRX standards today which no doubt explains the late price fall.
People spooked by lack of news about annual results so close to 6 month cut off? Or something more specific? Hopefully news on Monday.

cerrito
10/6/2025
07:41:01
Maybe a takeover is imminent and an important licence was gained by the buyer?
tnt99
09/6/2025
19:48:01
If they raise it may be along the lines of CRX a while back with Griffiths, Mills and Sneller. I took part and was well rewarded overall and final outcome was a sale to Evotec in Germany.
p1nkfish
09/6/2025
19:25:20
I had rather forgotten about them and the RNS this morning reminded me and I did a v modest top up.
I rechecked the quality of the Board and on paper they are v good. I was impressed by Glenn when he was at Consort. I need to say that I am abit perplexed that he did not sign off on the April 8th RNS on the ending of the strategic review as this is his job rather than the CEO.
I am not comfortable with the continued delay in getting the 2024 finals out- I see in the last 2 years they were out mid March which is what I would expect. One possible reason could be that they are having an issue with the auditors on the Going Concern statement and need to conclude a financing deal…but do not see this as being an issue here. I hope it is not due to issues unscrambling GBM V.
I can understand why Mr Mills is getting impatient..if he is..and I am sure that Messrs Sneller and Griffiths may be as well.
In some ways I can understand why they did not get much interest. Too small for established players..too small for people wanting to get into this competitive market and our friends in PE less gungho than before.

cerrito
09/6/2025
07:32:32
TU soon and good to see MDR announced today. Take with a pinch of salt but I do think this is close to the mark.

"With EU MDR approval, OrthoPure® XT can unlock:

A US $125–240 million direct market in European ACL reconstruction within a few years.

Supportive global niche (~US $30–;50 million) from the ACL graft market.

A stepping stone into broader knee biologics and multi‑ligament procedures in a US $2–4 billion+ opportunity across Europe.

These estimates align well with Tissue Regenix’s 2024-2030 strategic pillar to scale dCELL® products across EU and outside EU markets."

I suspect no sale of the company went through because of the price tag. TRX wouldn't sell themselves cheap given the potential. Some future time they will be acquired imho for a decent price compared to today - many multiples imho. Dyor etc as this may be totally wrong, just my thoughts.

p1nkfish
05/6/2025
10:17:18
I bought some today. A bit risky considering growth stalled badly in the second half but the company seems to believe it can return to growth and Chris Mills wants to sell.

Whatever happens the shares are not worthless.

arthur_lame_stocks
01/6/2025
09:55:10
Something towards 65.59% is in 3%+ holders and Directors.
The number of shares floating about is around 24.6M outside of those.

Peanuts in value but massive compared to average daily volume (30.5K approx over past 3 months). Some decent TU or transformational event/news needed else remains bombed-out and ignored.

p1nkfish
30/5/2025
12:33:08
I think probably re-iteration of previous guidance. It says it all unless some major news.
p1nkfish
30/5/2025
12:08:31
Next news is early June do we think?
dylanl2
30/5/2025
09:28:16
The whole of the health sector has been down or flat for last 3 years.United health group is the 2nd biggest company on the dow and are about 50% down. Link to United health group chart below
https://ibb.co/JR5qGF6P

mickhay3
15/5/2025
12:36:01
It looks to me like growth stalled in the second half.
arthur_lame_stocks
02/5/2025
12:37:57
Or taking them a long time to count the money lol
tnt99
02/5/2025
12:10:03
Or problems.
p1nkfish
02/5/2025
11:56:36
Possible bid maybe
tnt99
02/5/2025
11:56:15
Results must be being held back why?
tnt99
30/4/2025
17:21:08
Where are the annual results?
tnt99
24/4/2025
08:02:23
Why the weakness this company is profitable and growing must be a takeover target for a larger companyTo take control
tnt99
16/4/2025
14:01:09
Hopefully it can navigate them through production in both US and UK. I recall some of their products being assessed for approval to be licensed in China, for example, which UK production could perhaps meet.
onesock
15/4/2025
19:54:42
Will tissue regenix be effected by trump tarrifs even though it has a USA premises
tnt99
08/4/2025
11:53:19
Back up to 60p I hope at least!!
tnt99
08/4/2025
11:11:29
08/04/2025 07:00 RNS Regulatory News Tissue Regenix Group PLC Conclusion of Strategic Review & Offer Period LSE:TRX Tissue Regenix Group Plc

"... The Board believes the Company's valuation is now at a level which bears no resemblance to the prospects or the typical valuation that a business in this sector would be ascribed; the Board believes that despite varying degrees of interest in the Company, the current equity value cannot be used as a base from which a strategic transaction can occur. The Board, in conjunction with advisors and major shareholders, will continue to assess the best route forward to deliver the substantial value that exists in this business, which is not being reflected in the share price today.

The Board has determined that based on discussions to date, it does not believe there is a prospect of an appropriate offer for the issued, and to be issued, share capital of Tissue Regenix being forthcoming in the near term. Accordingly, the Company is no longer in discussions with any interested parties. ..."




The company is in effect saying that its AIM listing is scuppering any chance of a strategic transaction at a decent price, which is what they seem to want, to deliver greater value.

The logical conclusion from this therefore would be to delist, like so many other shares are doing at the moment.

So I think there's an odds-on possibility that this will happen, in the not too distant future.

hedgehog 100
08/4/2025
07:41:25
Could be interesting here after a big fall , only concern here is are the big shareholders planning to take this private ?
nchanning
Chat Pages: 597  596  595  594  593  592  591  590  589  588  587  586  Older

Top Brokers in the UK

Spread Bet
CFD
Forex
Share

Your Recent History

Delayed Upgrade Clock